282 related articles for article (PubMed ID: 12560328)
21. AT-hook DNA-binding motif-containing protein one knockdown downregulates EWS-FLI1 transcriptional activity in Ewing's sarcoma cells.
Kitagawa T; Kobayashi D; Baron B; Okita H; Miyamoto T; Takai R; Paudel D; Ohta T; Asaoka Y; Tokunaga M; Nakagawa K; Furutani-Seiki M; Araki N; Kuramitsu Y; Kobayashi M
PLoS One; 2022; 17(10):e0269077. PubMed ID: 36194562
[TBL] [Abstract][Full Text] [Related]
22. Alteration of mesodermal cell differentiation by EWS/FLI-1, the oncogene implicated in Ewing's sarcoma.
Eliazer S; Spencer J; Ye D; Olson E; Ilaria RL
Mol Cell Biol; 2003 Jan; 23(2):482-92. PubMed ID: 12509448
[TBL] [Abstract][Full Text] [Related]
23. Transcription factor ZBP-89 cooperates with histone acetyltransferase p300 during butyrate activation of p21waf1 transcription in human cells.
Bai L; Merchant JL
J Biol Chem; 2000 Sep; 275(39):30725-33. PubMed ID: 10899165
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
[TBL] [Abstract][Full Text] [Related]
25. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis.
Ma Y; Baltezor M; Rajewski L; Crow J; Samuel G; Staggs VS; Chastain KM; Toretsky JA; Weir SJ; Godwin AK
J Mol Med (Berl); 2019 Jul; 97(7):957-972. PubMed ID: 31025088
[TBL] [Abstract][Full Text] [Related]
26. Treatment of Ewing's sarcoma using an antisense oligodeoxynucleotide to regulate the cell cycle.
Asami S; Chin M; Shichino H; Yoshida Y; Nemoto N; Mugishima H; Suzuki T
Biol Pharm Bull; 2008 Mar; 31(3):391-4. PubMed ID: 18310898
[TBL] [Abstract][Full Text] [Related]
27. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells.
Tanaka K; Iwakuma T; Harimaya K; Sato H; Iwamoto Y
J Clin Invest; 1997 Jan; 99(2):239-47. PubMed ID: 9005992
[TBL] [Abstract][Full Text] [Related]
28. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
29. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma.
Lin PP; Brody RI; Hamelin AC; Bradner JE; Healey JH; Ladanyi M
Cancer Res; 1999 Apr; 59(7):1428-32. PubMed ID: 10197607
[TBL] [Abstract][Full Text] [Related]
30. The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing's sarcoma.
Sengupta A; Rahman M; Mateo-Lozano S; Tirado OM; Notario V
Int J Oncol; 2013 Sep; 43(3):803-12. PubMed ID: 23857410
[TBL] [Abstract][Full Text] [Related]
31. Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.
de Alava E; Panizo A; Antonescu CR; Huvos AG; Pardo-Mindán FJ; Barr FG; Ladanyi M
Am J Pathol; 2000 Mar; 156(3):849-55. PubMed ID: 10702401
[TBL] [Abstract][Full Text] [Related]
32. Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma.
Ban J; Jug G; Mestdagh P; Schwentner R; Kauer M; Aryee DN; Schaefer KL; Nakatani F; Scotlandi K; Reiter M; Strunk D; Speleman F; Vandesompele J; Kovar H
Oncogene; 2011 May; 30(18):2173-80. PubMed ID: 21217773
[TBL] [Abstract][Full Text] [Related]
33. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.
Grohar PJ; Woldemichael GM; Griffin LB; Mendoza A; Chen QR; Yeung C; Currier DG; Davis S; Khanna C; Khan J; McMahon JB; Helman LJ
J Natl Cancer Inst; 2011 Jun; 103(12):962-78. PubMed ID: 21653923
[TBL] [Abstract][Full Text] [Related]
34. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.
Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V
Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing's sarcoma.
Tosso PN; Kong Y; Scher L; Cummins R; Schneider J; Rahim S; Holman KT; Toretsky J; Wang K; Üren A; Brown ML
J Med Chem; 2014 Dec; 57(24):10290-303. PubMed ID: 25432018
[TBL] [Abstract][Full Text] [Related]
36. EWS/ETS fusions activate telomerase in Ewing's tumors.
Takahashi A; Higashino F; Aoyagi M; Yoshida K; Itoh M; Kyo S; Ohno T; Taira T; Ariga H; Nakajima K; Hatta M; Kobayashi M; Sano H; Kohgo T; Shindoh M
Cancer Res; 2003 Dec; 63(23):8338-44. PubMed ID: 14678994
[TBL] [Abstract][Full Text] [Related]
37. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma.
Kinsey M; Smith R; Iyer AK; McCabe ER; Lessnick SL
Cancer Res; 2009 Dec; 69(23):9047-55. PubMed ID: 19920188
[TBL] [Abstract][Full Text] [Related]
38. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.
Rao DD; Jay C; Wang Z; Luo X; Kumar P; Eysenbach H; Ghisoli M; Senzer N; Nemunaitis J
Mol Ther; 2016 Aug; 24(8):1412-22. PubMed ID: 27166877
[TBL] [Abstract][Full Text] [Related]
39. A molecular function map of Ewing's sarcoma.
Kauer M; Ban J; Kofler R; Walker B; Davis S; Meltzer P; Kovar H
PLoS One; 2009; 4(4):e5415. PubMed ID: 19404404
[TBL] [Abstract][Full Text] [Related]
40. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
